MedTrace Logo

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2025-12-02

No results posted yet for this study

Summary

There is no data comparing the effectiveness of the 4 most relevant first-line therapy programs for peripheral T-cell lymphomas (CHOEP, CHOP, CHEP-BV, CHP-BV) in a single study.

For the first time, the effectiveness and toxicity of various first-line PTCL therapy programs in patients with T-cell lymphoma will be analyzed in the conditions of a single medical center of the N.N.Petrov National Research Medical Center of Oncology and optimal therapeutic tactics will be determined, taking into account significant prognostic factors based on effectiveness and toxicity a specific chemotherapy regimen.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

Doxorubicin

doxorubicin 50 mg/m2, day 1

DRUG

Vincristine

vincristine 1.4 mg/m2, (maximum dose 2 mg) day 1

DRUG

Etoposide

Etoposide 100 mg/m2, 1-3 days

DRUG

cyclophosphamide

cyclophosphamide 750 mg/m2, day 1

DRUG

Prednisone

prednisone 100 mg, 1-5 days

DRUG

Brentuximab Vedotin (Bv)

brentuximab vedotin 1.8 mg / kg, day 1

Sponsors & Collaborators

  • N.N. Petrov National Medical Research Center of Oncology

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07258680 on ClinicalTrials.gov